Tan ASH, Saafan TSM, Ashoush F, Mahawar K. What bariatric surgery can teach us about glucagon-like peptide-1 agonist weight loss therapy: Improving long-term outcomes and patient care. World J Clin Cases 2026; 14(20): 121701 [DOI: 10.12998/wjcc.121701]
Corresponding Author of This Article
Tamer Saafan Moustafa Saafan, FRCS, Upper GI Surgery, South Tyneside and Sunderland NHS Foundation Trust, Harton Ln, Sunderland SR4 7TP, United Kingdom. tsaafan@gmail.com
Research Domain of This Article
Surgery
Article-Type of This Article
review-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Tan ASH, Saafan TSM, Ashoush F, Mahawar K. What bariatric surgery can teach us about glucagon-like peptide-1 agonist weight loss therapy: Improving long-term outcomes and patient care. World J Clin Cases 2026; 14(20): 121701 [DOI: 10.12998/wjcc.121701]
Arianna Sze Huey Tan, Tamer Saafan Moustafa Saafan, Kamal Mahawar, Upper GI Surgery, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, United Kingdom
Fouad Ashoush, Upper GI Surgery, Northumbria Healthcare NHS Foundation Trust, Cramlington NE23 6NZ, Northumberland, United Kingdom
Co-first authors: Arianna Sze Huey Tan and Tamer Saafan Moustafa Saafan.
Author contributions: Mahawar K formulated the concept of this review; Tan ASH, Saafan TSM, and Mahawar K performed editing and reviewing the literature; Tan ASH and Saafan TSM performed methodology searching; Tan ASH, Saafan TSM, and Ashoush F completed the literature search and review. All authors prepared the draft and approved the submitted version. Tan ASH and Saafan TSM contributed equally to the manuscript.
AI contribution statement: AI tools (specifically ChatGPT) were used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Corresponding author: Tamer Saafan Moustafa Saafan, FRCS, Upper GI Surgery, South Tyneside and Sunderland NHS Foundation Trust, Harton Ln, Sunderland SR4 7TP, United Kingdom. tsaafan@gmail.com
Received: March 31, 2026 Revised: May 10, 2026 Accepted: June 12, 2026 Published online: July 16, 2026 Processing time: 100 Days and 22 Hours
Core Tip
Core Tip: Obesity is a prevalent chronic disease associated with significant metabolic and psychosocial morbidity. While metabolic bariatric surgery (MBS) remains the most effective treatment, incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists, are increasingly used. However, these agents are relatively new, with limited long-term data and risks related to rapid weight loss, including nutritional deficiencies, lean mass loss, and psychosocial effects-well recognised in bariatric practice. Unlike MBS, which benefits from structured follow-up and multidisciplinary care, pharmacotherapy pathways often lack equivalent monitoring and support. This review explores how bariatric principles can improve the safety and long-term outcomes of anti-obesity medication use.
